Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Labgenomics Co., Ltd. (084650:KRX), powered by AI.
Labgenomics Co., Ltd. is currently trading at ₩1,077. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Labgenomics Co., Ltd. on Alpha Lenz.
Labgenomics Co., Ltd.'s P/E ratio is -1.2.
“Labgenomics Co., Ltd. trades at a P/E of -1.2 (undervalued) with modest ROE of -35.2%.”
Ask for details →Labgenomics Co., Ltd. is a prominent biotechnology company that focuses on offering innovative diagnostic solutions through advanced genetic testing technologies. The primary function of Labgenomics is to develop and commercialize DNA-based testing systems which are critical for early disease detection and personalized medicine. The company is deeply involved in the healthcare and life sciences sectors, providing vital tools for genetic screening, cancer diagnostics, and prenatal testing. A notable feature of Labgenomics is its commitment to improving accuracy and accessibility in genetic diagnostics, which positions it as a key player in fostering precision medicine. As a part of the broader biopharmaceutical and healthcare ecosystem, Labgenomics plays a crucial role in enhancing patient outcomes via cutting-edge research and development. Its impact is significant for medical institutions, clinicians, and researchers who rely on robust genetic data to make informed decisions. Founded in South Korea, Labgenomics continues to advance the field of genomic diagnostics, contributing to the global push towards data-driven health solutions.
“Labgenomics Co., Ltd. trades at a P/E of -1.2 (undervalued) with modest ROE of -35.2%.”
Ask for details →Labgenomics Co., Ltd. (ticker: 084650) is a company listed on KRX in the Common Stock sector (Common Stock). Market cap is $80.0B.
The current price is ₩1,077 with a P/E ratio of -1.24x and P/B of 0.53x.
ROE is -35.18% and operating margin is -60.70%. Annual revenue is $88.2B.